ADE? Or ADR? Medication Error Case Studies for Successful EU Compliance
Product Details
Two months ago, this wouldn’t have been your problem to report. Today it is!
Drugmakers, contract manufacturers and physicians are always monitoring, investigating and reporting adverse drug events (ADEs) — only now drugmakers must report medication errors as adverse drug reactions (ADRs). Reporting is required as soon as possible, but no more than 15 calendar days after initial report to a pharmacovigilance center or to the marketing authorization holder.
Listen today as a top drug development consultant illustrates some of the many danger situations you may face.
These are case studies — actual, not hypothetical. Presenter Dr. Hoss Dowlat, Ph.D. has taken them from his 31+ years involved in drug development in the EU region and North America.
And that’s not all. You’ll discover the regulatory background behind this new EU crackdown, and how to shift your pharmacovigilance focus from products to patients. Check out this agenda:
- Updates from the May 2013 EMA medication errors workshop
- 9 factors that increase medication errors in the product lifecycle and special populations
- What aspects of reporting have changed
- What medication errors are, and why they weren’t formerly considered ADRs
- Novel perspectives of EU vs. U.S. perspectives on medication safety
- Why the EU is adopting the FDA’s risk mitigation tools
- The EU patient leaflet — an overlooked opportunity for risk minimization?
- And much more
One medication mixup that leads to hospitalization, disfigurement or death could cost millions upon millions of dollars. It’s not a risk worth taking. If you face EU drug regulation of any kind, for any reason, you owe it to yourself to sign up TODAY!